HDFC Pharma And Healthcare Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹21.22-0.79%
07 Jul 2026
Loading…
Expense ratio of the scheme (1.15%) is higher than average expense ratio of the category (1.02%), excluding index funds and ETFs
This measures the relative expense of the scheme with respect to average expense ratio of the category. Investors should always prefer schemes with lower expense, everything else remaining the same
What is Expense ratio?
Since this is a relatively new scheme (less than 3 years), we do not have sufficient data to conduct meaningful performance analysis
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.